Buchang Pharmaceutical Overview

  • Year Founded
  • 1993

Year Founded

  • Status
  • Public

  • Employees
  • 8,311

Employees

  • Stock Symbol
  • 603858

Stock Symbol

  • Investments
  • 6

  • Share Price
  • $2.09
  • (As of Wednesday Closing)

Buchang Pharmaceutical General Information

Description

Shandong Buchang Pharmaceuticals Co Ltd is engaged in research and development, production and sales of Chinese patent medicines.

Contact Information

Website
www.buchang.com
Ownership Status
Publicly Held
Financing Status
Formerly PE-Backed
Corporate Office
  • No. 369 Zhonghua West Road
  • Heze, Shandong 274000
  • China
+86 0530
Primary Industry
Pharmaceuticals
Other Industries
Distributors (Healthcare)
Stock Exchange
SHG
Vertical(s)
Corporate Office
  • No. 369 Zhonghua West Road
  • Heze, Shandong 274000
  • China
+86 0530

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Buchang Pharmaceutical Stock Performance

As of 26-Mar-2025, Buchang Pharmaceutical’s stock price is $2.09. Its current market cap is $2.31B with 1.11B shares.

(As of Wednesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$2.09 $2.08 $1.98 - $2.81 $2.31B 1.11B 4.84M -$0.04

Buchang Pharmaceutical Financials Summary

As of 30-Sep-2024, Buchang Pharmaceutical has a trailing 12-month revenue of $1.64B.

In Thousands,
USD
TTM 30-Sep-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021
EV 3,096,641 2,930,512 3,407,298 4,113,853
Revenue 1,640,592 1,872,135 2,220,085 2,441,147
EBITDA (9,312) 152,404 (96,013) 346,993
Net Income (40,861) 45,085 (227,149) 179,976
Total Assets 2,873,361 2,947,309 3,181,755 3,743,039
Total Debt 545,376 444,622 456,999 555,216
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Buchang Pharmaceutical Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Buchang Pharmaceutical‘s full profile, request access.

Request a free trial

Buchang Pharmaceutical Patents

Buchang Pharmaceutical Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20230113539-A1 Traditional chinese medicine for dispersing lung qi and detoxicating Pending 07-Apr-2020
CA-3175596-A1 Traditional chinese medicine for dispersing lung qi and detoxicating Pending 07-Apr-2020

Buchang Pharmaceutical Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Buchang Pharmaceutical Investments (6)

Buchang Pharmaceutical’s most recent deal was a Early Stage VC with OncoResponse for . The deal was made on 14-Jun-2019.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
OncoResponse 14-Jun-2019 Early Stage VC Drug Discovery
YoDo International Education 27-Mar-2018 Later Stage VC Information Services (B2C)
Bubi 01-Nov-2017 Early Stage VC Financial Software
Symbow Medical 18-Jul-2017 Later Stage VC Diagnostic Equipment
Kfyao 18-Apr-2017 Early Stage VC Other Healthcare Technology Systems
You’re viewing 5 of 6 investments. Get the full list »

Buchang Pharmaceutical ESG

Risk Overview

Risk Rating

Updated December, 20, 2024

43.07 | Severe Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 14,946

Rank

Percentile

Pharmaceuticals

Industry

of 847

Rank

Percentile

Pharmaceuticals

Subindustry

of 421

Rank

Percentile

To view Buchang Pharmaceutical’s complete esg history, request access »

Buchang Pharmaceutical Exits (1)

Buchang Pharmaceutical’s most recent exit was on 18-Apr-2017 from Kfyao. The exit was categorized as .

Company Name Exit Date Exit Type Exit Size Status Buyers
Kfyao 18-Apr-2017 Completed
To view Buchang Pharmaceutical’s complete exits history, request access »

Buchang Pharmaceutical FAQs

  • When was Buchang Pharmaceutical founded?

    Buchang Pharmaceutical was founded in 1993.

  • Where is Buchang Pharmaceutical headquartered?

    Buchang Pharmaceutical is headquartered in Heze, China.

  • What is the size of Buchang Pharmaceutical?

    Buchang Pharmaceutical has 8,311 total employees.

  • What industry is Buchang Pharmaceutical in?

    Buchang Pharmaceutical’s primary industry is Pharmaceuticals.

  • Is Buchang Pharmaceutical a private or public company?

    Buchang Pharmaceutical is a Public company.

  • What is Buchang Pharmaceutical’s stock symbol?

    The ticker symbol for Buchang Pharmaceutical is 603858.

  • What is the current stock price of Buchang Pharmaceutical?

    As of 26-Mar-2025 the stock price of Buchang Pharmaceutical is $2.09.

  • What is the current market cap of Buchang Pharmaceutical?

    The current market capitalization of Buchang Pharmaceutical is $2.31B.

  • What is Buchang Pharmaceutical’s current revenue?

    The trailing twelve month revenue for Buchang Pharmaceutical is $1.64B.

  • What is Buchang Pharmaceutical’s annual earnings per share (EPS)?

    Buchang Pharmaceutical’s EPS for 12 months was -$0.04.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »